PREVIOUS
✖
New Alzheimer drug
October 6 , 2025
14 hrs 0 min
17
0
- Lecanemab is a lab-made antibody drug that slows early-stage Alzheimer’s by targeting amyloid proteins in the brain.
- It was approved by Australia.
- This can only be used in the early stages of Alzheimer’s.
- Side effects include brain swelling in 12.6 percent of patients and a higher risk in those with the ApoE4 gene.
- Dementia is a condition that results in progressive memory or thinking problems.
Leave a Reply
Your Comment is awaiting moderation.